romosozumab HCP administration with PFS

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Post-Menopausal Osteoporosis

Drug Information

Target Indication

Post-Menopausal Osteoporosis

Clinical Trial

Last updated: 6/30/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA12/9/2019

Evenity

Evenity is indicated in treatment of severe osteoporosis in postmenopausal women at high risk of fracture.

Drug Science

Mechanism of action & safety profile

Developer

AMGN

Amgen Inc.

Related Pipeline

Breast Cancer

Small Cell Lung Cancer

Postmenopausal Osteoporosis

Rheumatoid Arthritis

Anemia

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts